Squadron Capital Management Reports New 9.9% Stake in Aprea Therapeutics via Warrants

On April 7, 2026, Squadron Capital Management, LLC, along with Squadron Master Fund LP, Matthew Sesterhenn, and William Blank, filed a Schedule 13G reporting a new 9.9% ownership stake in Aprea Therapeutics, Inc. (APRE). The reporting group beneficially owns 1,271,081 shares of Common Stock, which consists entirely of shares issuable upon the exercise of warrants. This position was established following an event on March 30, 2026. Squadron Capital Management, LLC acts as the investment adviser to the Funds, including Squadron Master Fund LP. Matthew Sesterhenn and William Blank, as partners of the investment adviser, share voting and dispositive power over the securities. The filing indicates that the shares were acquired for investment purposes and not with the intent to influence or change the control of the issuer. The ownership percentage is based on approximately 11.45 million shares outstanding as of mid-March 2026, adjusted for the shares issuable upon warrant exercise.